Beyond dose. Perceived group support as a person-level predictor of emotional breakthrough and psychological insight during DMT–harmine administration
Preprint
- 10 November 2026
- preprint
- Published by Springer Nature in Research Square
Abstract
Dose-escalation studies with dimethyltryptamine (DMT) show robust increases in emotional breakthrough, mystical experience, and psychological insight at higher doses, but with substantial inter-individual variability, suggesting factors beyond pharmacology shape response profiles. Growing evidence points to the clinical relevance of social factors, especially in group-based psychedelic therapy. Using data from a randomized-controlled trial, we investigated oromucosal DMT-harmine administration in a group setting and identified a three-layer architecture of acute psychedelic experience. First, dose scaled all three primary subjective outcomes. Second, perceived group support, reflecting stable between-person differences rather than session-to-session fluctuations, accounted for a substantial share of dose-independent between-subject variance in emotional breakthrough and psychological insight, though not in mystical-type experience. Third, pre-session affective personality, indexed by an approach-withdrawal composite, predicted group appraisal, with more approach-oriented profiles linked to more favorable perceptions of the group context. We situate these findings within the current research landscape and discuss the clinical implications of this three-layer framework for acute psychedelic experience.All Related Versions
This publication has 54 references indexed in Scilit:
- Population pharmacokinetic-pharmacodynamic modeling of co-administered N,N-dimethyltryptamine and harmine in healthy subjectsBiomedicine & Pharmacotherapy, 2025
- Examining the pharmacokinetic and pharmacodynamic interaction of N,N-dimethyltryptamine and harmine in healthy volunteers: Α factorial dose-escalation studyBiomedicine & Pharmacotherapy, 2025
- Set and Setting for Psychedelic Harm Reduction2024
- Therapeutic frameworks in integration sessions in substance‐assisted psychotherapy: A systematised reviewClinical Psychology & Psychotherapy, 2023
- Acceptability of psilocybin‐assisted group therapy in patients with cancer and major depressive disorder: Qualitative analysisCancer, 2023
- Psilocybin‐assisted group therapy in patients with cancer diagnosed with a major depressive disorderCancer, 2023
- Psilocybin therapy for treatment resistant depression: prediction of clinical outcome by natural language processingPsychopharmacology, 2023
- Calcium Phosphate Microcapsules as Multifunctional Drug Delivery DevicesAdvanced Functional Materials, 2023
- Pharmacokinetics of N,N-dimethyltryptamine in HumansEuropean Journal of Drug Metabolism and Pharmacokinetics, 2023
- Applying Lessons From Cannabis to the Psychedelic HighwayJAMA Health Forum, 2022